|
US2809918A
(en)
|
1955-10-17 |
1957-10-15 |
Victor M Hermelin |
Sustained release pharmaceutical preparations
|
|
DE2010416B2
(de)
|
1970-03-05 |
1979-03-29 |
Hoechst Ag, 6000 Frankfurt |
Oral anwendbare Arzneiform mit Retardwirkung
|
|
US3760984A
(en)
|
1971-09-29 |
1973-09-25 |
Alza Corp |
Osmotically powered agent dispensing device with filling means
|
|
US4107288A
(en)
|
1974-09-18 |
1978-08-15 |
Pharmaceutical Society Of Victoria |
Injectable compositions, nanoparticles useful therein, and process of manufacturing same
|
|
US3952741A
(en)
|
1975-01-09 |
1976-04-27 |
Bend Research Inc. |
Controlled release delivery system by an osmotic bursting mechanism
|
|
US4082819A
(en)
|
1977-03-02 |
1978-04-04 |
The Standard Oil Company |
Rubber-modified acrylonitrile-vinyl ether-indene polymers
|
|
JPS5663950A
(en)
|
1979-10-30 |
1981-05-30 |
Mitsubishi Chem Ind Ltd |
Cyclopropanecarboxylic ester
|
|
FR2535721A1
(fr)
|
1982-11-08 |
1984-05-11 |
Sanofi Sa |
Derives de la piperidinedione protecteurs du myocarde presentant une acticite antiarythmique, leur procede de preparation et les medicaments qui contiennent lesdits derives
|
|
US4911920A
(en)
|
1986-07-30 |
1990-03-27 |
Alcon Laboratories, Inc. |
Sustained release, comfort formulation for glaucoma therapy
|
|
US4728512A
(en)
|
1985-05-06 |
1988-03-01 |
American Home Products Corporation |
Formulations providing three distinct releases
|
|
FR2588189B1
(fr)
|
1985-10-03 |
1988-12-02 |
Merck Sharp & Dohme |
Composition pharmaceutique de type a transition de phase liquide-gel
|
|
US4794001A
(en)
|
1986-03-04 |
1988-12-27 |
American Home Products Corporation |
Formulations providing three distinct releases
|
|
JP2518353B2
(ja)
|
1988-06-09 |
1996-07-24 |
住友化学工業株式会社 |
シアノ酢酸アミド誘導体およびその製造中間体
|
|
CA2018801C
(fr)
|
1990-06-12 |
2000-08-22 |
Pierre Louis Beaulieu |
Derives peptidiques comprenant une terminaison-n1,4-dioxo-c4
|
|
JPH04177244A
(ja)
|
1990-11-10 |
1992-06-24 |
Konica Corp |
ハロゲン化銀写真感光材料
|
|
CA2033447C
(fr)
|
1990-12-31 |
1999-08-31 |
Robert Deziel |
Complexe synergique pour le traitement des infections herpetiques
|
|
ATE141502T1
(de)
|
1991-01-15 |
1996-09-15 |
Alcon Lab Inc |
Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
|
|
US5145684A
(en)
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
|
US5212162A
(en)
|
1991-03-27 |
1993-05-18 |
Alcon Laboratories, Inc. |
Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
|
|
JPH05301838A
(ja)
|
1991-10-15 |
1993-11-16 |
Mitsubishi Kasei Corp |
スチレン誘導体
|
|
US5792771A
(en)
|
1992-11-13 |
1998-08-11 |
Sugen, Inc. |
Quinazoline compounds and compositions thereof for the treatment of disease
|
|
AU2096895A
(en)
|
1994-03-07 |
1995-09-25 |
Sugen, Incorporated |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
|
JPH0827090A
(ja)
|
1994-05-13 |
1996-01-30 |
Sumitomo Chem Co Ltd |
シアノ酢酸アミド誘導体、その用途およびその製造中間体
|
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
PL335839A1
(en)
|
1997-03-14 |
2000-05-22 |
Basf Ag |
Cycloalkylalkane carboxamides as well as their production and application
|
|
US7863444B2
(en)
|
1997-03-19 |
2011-01-04 |
Abbott Laboratories |
4-aminopyrrolopyrimidines as kinase inhibitors
|
|
IL125947A0
(en)
|
1997-09-17 |
1999-04-11 |
American Cyanamid Co |
3-(1,2-benzisothiazol- and isoxazol-5-yl)-2,4(1h,3h)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3)-pyrimidinone or thione herbicidal agents
|
|
DE69814122T2
(de)
|
1997-10-09 |
2004-03-18 |
Dexcel Pharma Technologies Ltd. |
Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt
|
|
US6713474B2
(en)
|
1998-09-18 |
2004-03-30 |
Abbott Gmbh & Co. Kg |
Pyrrolopyrimidines as therapeutic agents
|
|
CN1348370A
(zh)
|
1999-04-15 |
2002-05-08 |
布里斯托尔-迈尔斯斯奎布公司 |
环状蛋白酪氨酸激酶抑制剂
|
|
DE60004685T2
(de)
|
1999-09-17 |
2004-07-29 |
Abbott Gmbh & Co. Kg |
Pyrazolopyrimidine als arzneimittel
|
|
WO2001072751A1
(fr)
|
2000-03-29 |
2001-10-04 |
Knoll Gesellschaft Mit Beschraenkter Haftung |
Pyrrolopyrimidines utilisees comme inhibiteurs de tyrosine kinases
|
|
AR042586A1
(es)
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
|
MXPA03008560A
(es)
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
|
EP1451173A4
(fr)
|
2001-11-01 |
2005-10-26 |
Icagen Inc |
Piperidines
|
|
JP3991812B2
(ja)
|
2001-12-11 |
2007-10-17 |
住友化学株式会社 |
エステル化合物およびその用途
|
|
WO2003068157A2
(fr)
|
2002-02-11 |
2003-08-21 |
The Brigham And Women's Hospital, Inc. |
Inhibiteurs de kinase et leurs procedes d'utilisation
|
|
NI200300043A
(es)
|
2002-03-28 |
2003-11-05 |
Warner Lambert Co |
AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
|
|
FR2842735B1
(fr)
|
2002-07-26 |
2006-01-06 |
Flamel Tech Sa |
Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
|
|
US7419981B2
(en)
|
2002-08-15 |
2008-09-02 |
Pfizer Inc. |
Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
|
|
GB0219024D0
(en)
|
2002-08-15 |
2002-09-25 |
Pfizer Ltd |
Synergistic combinations
|
|
GB0226370D0
(en)
|
2002-11-12 |
2002-12-18 |
Novartis Ag |
Organic compounds
|
|
EP1597256A1
(fr)
|
2003-02-21 |
2005-11-23 |
Pfizer Inc. |
Derives d'amino-thiazole substitues par n-heterocyclyle en tant qu'inhibiteurs de la proteine kinase
|
|
WO2004100868A2
(fr)
|
2003-04-23 |
2004-11-25 |
Abbott Laboratories |
Procede servant a traiter le rejet d'un transplant
|
|
DE602004009582T2
(de)
|
2003-08-01 |
2009-01-02 |
Chugai Seiyaku K.K. |
Cyanoamid-verbindungen als nützliche malonyl-coa decarboxylase-hemmer
|
|
BRPI0414082A
(pt)
|
2003-09-02 |
2006-10-24 |
Pfizer Prod Inc |
formas de dosagem de liberação sustentada de ziprasidona
|
|
WO2005023773A1
(fr)
|
2003-09-04 |
2005-03-17 |
Pfizer Limited |
Procede pour la preparation d'arylpyrazoles substitues
|
|
GB0322140D0
(en)
|
2003-09-22 |
2003-10-22 |
Pfizer Ltd |
Combinations
|
|
JP2007506726A
(ja)
|
2003-09-25 |
2007-03-22 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
α２δ−タンパク質に対する親和性を有するアミノ酸の使用方法
|
|
EP1730148A4
(fr)
|
2004-02-03 |
2009-08-19 |
Abbott Lab |
Utilisation d'aminobenzoxazoles comme agents therapeutiques
|
|
JP4552456B2
(ja)
|
2004-02-27 |
2010-09-29 |
住友化学株式会社 |
エステル化合物およびその用途
|
|
JPWO2005085210A1
(ja)
|
2004-03-10 |
2008-01-17 |
小野薬品工業株式会社 |
ニトリル化合物およびその化合物を有効成分として含有する医薬組成物
|
|
US20060045822A1
(en)
|
2004-09-01 |
2006-03-02 |
Board Of Regents, The University Of Texas System |
Plasma polymerization for encapsulating particles
|
|
US7807719B2
(en)
|
2004-09-14 |
2010-10-05 |
Chaim Roifman |
Compounds useful for modulating abnormal cell proliferation
|
|
JP2008514635A
(ja)
|
2004-09-27 |
2008-05-08 |
コーザン バイオサイエンシス インコーポレイテッド |
特異的キナーゼ阻害剤
|
|
CA2597587A1
(fr)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Composes cycliques imidazo[4,5-c] substitues par oxime et hydroxylamine et procedes associes
|
|
CA2603105A1
(fr)
|
2005-03-28 |
2006-10-05 |
Dexcel Pharma Technologies Ltd. |
Absorption regulee de statines dans l'intestin
|
|
EP2029138A1
(fr)
|
2005-06-03 |
2009-03-04 |
Xenon Pharmaceuticals Inc. |
Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine
|
|
US20070149464A1
(en)
|
2005-06-15 |
2007-06-28 |
Pfizer Inc. |
Combination
|
|
US20080146643A1
(en)
|
2005-06-15 |
2008-06-19 |
Pfizer Limited |
Combination
|
|
US7645786B2
(en)
|
2005-06-15 |
2010-01-12 |
Pfizer Inc. |
Substituted arylpyrazoles
|
|
CN101228134A
(zh)
|
2005-06-15 |
2008-07-23 |
辉瑞有限公司 |
用作杀寄生虫剂的取代芳基吡唑
|
|
US20080176865A1
(en)
|
2005-06-15 |
2008-07-24 |
Pfizer Limited |
Substituted arylpyrazoles
|
|
WO2007043400A1
(fr)
|
2005-10-07 |
2007-04-19 |
Kissei Pharmaceutical Co., Ltd. |
Compose heterocyclique aromatique azote et composition pharmaceutique le contenant
|
|
ES2432361T3
(es)
|
2005-12-02 |
2013-12-03 |
Bayer Healthcare, Llc |
Derivados de pirrolotriazina útiles para el tratamiento de cáncer por inhibición de cinasa Aurora
|
|
CN101421269A
(zh)
|
2006-01-13 |
2009-04-29 |
环状药物公司 |
酪氨酸激酶抑制剂及其用途
|
|
AU2007234455B2
(en)
|
2006-03-31 |
2012-10-04 |
The Board Of Regents Of The University Of Texas System |
Orally bioavailable caffeic acid related anticancer drugs
|
|
US7645748B2
(en)
|
2006-04-03 |
2010-01-12 |
Forbes Medi-Tech Inc. |
Sterol/stanol phosphorylnitroderivatives and use thereof
|
|
EP2029597A4
(fr)
|
2006-05-31 |
2011-11-23 |
Univ California |
Analogues de la purine
|
|
US20100292229A1
(en)
|
2006-06-30 |
2010-11-18 |
The Board Of Regents Of The University Of Texas System |
Tryphostin-analogs for the treatment of cell proliferative diseases
|
|
NZ573979A
(en)
|
2006-07-06 |
2012-02-24 |
Array Biopharma Inc |
Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
|
|
PT2201840E
(pt)
|
2006-09-22 |
2012-02-14 |
Pharmacyclics Inc |
Inibidores da tirosina quinase de bruton
|
|
EP2089391B1
(fr)
|
2006-11-03 |
2013-01-16 |
Pharmacyclics, Inc. |
Sonde d'activité de la tyrosine kinase de bruton et son procédé d'utilisation
|
|
MX2009005363A
(es)
|
2006-11-23 |
2009-06-05 |
Novartis Ag |
Pirimidinas y su uso como antagonistas del receptor cxcr2.
|
|
EP2125819B1
(fr)
|
2007-03-21 |
2014-10-22 |
Bristol-Myers Squibb Company |
Composés hétérocycliques fusionnés utiles pour le traitement de maladies prolifératives, allergiques, auto-immunes ou inflammatoires
|
|
GB2447933A
(en)
|
2007-03-27 |
2008-10-01 |
Chemence Ltd |
Cyanoacrylate monomer for forming an adhesive polymer
|
|
EA017865B1
(ru)
*
|
2007-03-28 |
2013-03-29 |
Фармасайкликс, Инк. |
Ингибиторы тирозинкиназы брутона
|
|
CN101952294B
(zh)
|
2008-02-25 |
2014-11-26 |
霍夫曼-拉罗奇有限公司 |
吡咯并吡嗪激酶抑制剂
|
|
PL2247592T3
(pl)
|
2008-02-25 |
2012-01-31 |
Hoffmann La Roche |
Pirolopirazynowe inhibitory kinazy
|
|
BRPI0912668A2
(pt)
|
2008-05-13 |
2016-01-26 |
Irm Llc |
composto e composições como inibidores de quinase
|
|
US8691838B2
(en)
|
2008-05-22 |
2014-04-08 |
Amgen Inc. |
Heterocycles as protein kinase inhibitors
|
|
AU2009270856B2
(en)
|
2008-07-16 |
2013-07-25 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
|
|
US20110165183A1
(en)
|
2008-08-01 |
2011-07-07 |
Biocryst Pharmaceuticals, Inc. |
Piperidine derivatives as jak3 inhibitors
|
|
US8450337B2
(en)
|
2008-09-30 |
2013-05-28 |
Moleculin, Llc |
Methods of treating skin disorders with caffeic acid analogs
|
|
US20100113520A1
(en)
|
2008-11-05 |
2010-05-06 |
Principia Biopharma, Inc. |
Kinase knockdown via electrophilically enhanced inhibitors
|
|
US20120028981A1
(en)
|
2008-11-05 |
2012-02-02 |
Principia Biopharma Inc. |
Kinase Knockdown Via Electrophilically Enhanced Inhibitors
|
|
US8426428B2
(en)
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
|
JP2013504325A
(ja)
|
2009-09-09 |
2013-02-07 |
アビラ セラピューティクス， インコーポレイテッド |
Ｐｉ３キナーゼインヒビターおよびその使用
|
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
|
AU2010319964A1
(en)
|
2009-11-16 |
2012-06-07 |
The Regents Of The University Of California |
Kinase inhibitors
|
|
JP2013529204A
(ja)
|
2010-05-20 |
2013-07-18 |
エフ．ホフマン−ラ ロシュ アーゲー |
ピロロ［２，３−ｂ］ピラジン−７−カルボキサミド誘導体とＪＡＫ及びＳＹＫ及び阻害剤としてのそれらの使用
|
|
MY169745A
(en)
|
2010-05-31 |
2019-05-14 |
Ono Pharmaceutical Co |
Purinone derivative
|
|
EA201890869A3
(ru)
*
|
2010-06-03 |
2019-03-29 |
Фармасайкликс, Инк. |
Применение ингибиторов тирозинкиназы брутона (btk)
|
|
US20120071497A1
(en)
|
2010-06-03 |
2012-03-22 |
Pharmacyclics, Inc. |
Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
|
|
CN101880243A
(zh)
|
2010-06-04 |
2010-11-10 |
贵阳柏丝特化工有限公司 |
一种含氟氰拟除虫菊酯化合物及其合成方法与用途
|
|
RU2013109393A
(ru)
|
2010-08-10 |
2014-09-20 |
Сэлджин Авиаломикс Ресеарч, Инк. |
Безилатная соль ингибитора втк
|
|
ES2770550T3
(es)
*
|
2011-05-17 |
2020-07-02 |
Univ California |
Inhibidores de quinasa
|
|
PL2710005T3
(pl)
|
2011-05-17 |
2017-07-31 |
Principia Biopharma Inc. |
Inhibitory kinazy tyrozynowej
|
|
US9376438B2
(en)
|
2011-05-17 |
2016-06-28 |
Principia Biopharma, Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
|
US20140107151A1
(en)
|
2011-05-17 |
2014-04-17 |
Principia Biophama Inc. |
Tyrosine kinase inhibitors
|
|
US8828426B2
(en)
|
2011-06-07 |
2014-09-09 |
Zx Pharma, Llc |
Multiparticulate L-carnitine compositions and related methods
|
|
AU2012275275A1
(en)
|
2011-06-28 |
2014-01-23 |
Pharmacyclics Llc |
Methods and compositions for inhibition of bone resorption
|
|
AU2012283775A1
(en)
|
2011-07-13 |
2014-01-23 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
JP5826931B2
(ja)
|
2011-07-19 |
2015-12-02 |
メルク・シャープ・エンド・ドーム・ベー・フェー |
Ｂｔｋ阻害剤としての４−イミダゾピリダジン−１−イル−ベンズアミドおよび４−イミダゾトリアジン−１−イル−ベンズアミド
|
|
WO2013010869A1
(fr)
|
2011-07-19 |
2013-01-24 |
Msd Oss B.V. |
4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides inhibiteurs de btk
|
|
EP2548877A1
(fr)
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK
|
|
JP2014531449A
(ja)
|
2011-09-20 |
2014-11-27 |
セルゾーム リミティッド |
キナーゼ阻害剤としてのピラゾロ［４，３―ｃ］ピリジン誘導体
|
|
KR102054468B1
(ko)
|
2011-10-19 |
2019-12-11 |
파마싸이클릭스 엘엘씨 |
브루톤 티로신 인산화효소(btk)의 억제제의 용도
|
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
|
US8501724B1
(en)
|
2012-01-31 |
2013-08-06 |
Pharmacyclics, Inc. |
Purinone compounds as kinase inhibitors
|
|
WO2013185082A2
(fr)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Inhibiteurs de la tyrosine kinase de bruton
|
|
AU2013277582B2
(en)
|
2012-06-18 |
2017-11-30 |
Principia Biopharma Inc. |
Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
|
|
US20150140085A1
(en)
|
2012-06-29 |
2015-05-21 |
Principia Biopharma Inc. |
Formulations comprising ibrutinib
|
|
US9572811B2
(en)
|
2012-08-03 |
2017-02-21 |
Principia Biopharma Inc. |
Treatment of dry eye
|
|
SMT201900344T1
(it)
|
2012-09-10 |
2019-07-11 |
Principia Biopharma Inc |
Composti di pirazolopirimidina come inibitori di chinasi
|
|
HK1211293A1
(en)
|
2012-11-02 |
2016-05-20 |
辉瑞公司 |
Bruton's tyrosine kinase inhibitors
|
|
JP2015537033A
(ja)
|
2012-11-15 |
2015-12-24 |
ファーマサイクリックス，インク． |
キナーゼ阻害剤としてのピロロピリミジン化合物
|
|
US20140142099A1
(en)
|
2012-11-20 |
2014-05-22 |
Principia Biopharma Inc. |
Purinone Derivatives as Tyrosine Kinase Inhibitors
|
|
JO3377B1
(ar)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
AU2015225745B2
(en)
|
2014-02-03 |
2017-04-20 |
Cadila Healthcare Limited |
Heterocyclic compounds
|
|
KR20220027271A
(ko)
|
2014-02-21 |
2022-03-07 |
프린시피아 바이오파마, 인코퍼레이티드 |
Btk 억제제의 염 및 고체 형태
|
|
CA2970723C
(fr)
|
2014-12-18 |
2023-09-05 |
Principia Biopharma Inc. |
Traitement du pemphigus
|
|
HUE061809T2
(hu)
|
2014-12-24 |
2023-08-28 |
Principia Biopharma Inc |
Készítmények csípõbél-éhbél szakaszba történõ hatóanyag beadáshoz
|
|
IL252913B
(en)
|
2014-12-24 |
2022-06-01 |
Principia Biopharma Inc |
Dose of site-specific btk inhibitor
|
|
KR20240070721A
(ko)
|
2015-06-03 |
2024-05-21 |
프린시피아 바이오파마, 인코퍼레이티드 |
티로신 키나제 억제제
|
|
MA42242A
(fr)
|
2015-06-24 |
2018-05-02 |
Principia Biopharma Inc |
Inhibiteurs de la tyrosine kinase
|
|
CN105753863B
(zh)
|
2015-09-11 |
2018-07-31 |
东莞市真兴贝特医药技术有限公司 |
氧代二氢咪唑并吡啶类化合物及其应用
|
|
US10358446B2
(en)
|
2015-10-14 |
2019-07-23 |
Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. |
Bruton's tyrosine kinase inhibitors
|
|
WO2018005849A1
(fr)
|
2016-06-29 |
2018-01-04 |
Principia Biopharma Inc. |
Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile
|